Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9438996 | 0.75 | ACE (0.66) | ACEMEN1USP2LMNAKMT2A | |
| SCHEMBL9439005 | 0.75 | ACE (0.66) | ACEMEN1USP2LMNAKMT2A | |
| SCHEMBL9439000 | 0.75 | ACE (0.66) | ACEMEN1USP2LMNAKMT2A | |
| SCHEMBL24302439 | 0.74 | F2 (0.43) | ACEMEN1USP2LMNAKMT2A | |
| SCHEMBL4437826 | 0.73 | ATM (0.53) | POLBFOLH1RIMKLANAALAD2 | |
| SCHEMBL4437822 | 0.73 | ATM (0.53) | POLBFOLH1RIMKLANAALAD2 | |
| SCHEMBL13609889 | 0.72 | ACE (0.47) | ACEPREPMEN1USP2LMNA | |
| SCHEMBL29511169 | 0.72 | ACE (0.47) | ACEPREPMEN1USP2LMNA | |
| SCHEMBL4800813 | 0.72 | ACE (0.47) | ACEPREPMEN1USP2LMNA | |
| SCHEMBL13448164 | 0.72 | ACE (0.43) | ACEMEN1USP2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | POLB 2527/4885ACE 85/4885FOLH1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.